Published in Heart on June 01, 2004
Five year outcome after primary coronary intervention for acute ST elevation myocardial infarction: results from a single centre experience. Heart (2005) 1.06
The prognostic effect of cardiac rehabilitation in the era of acute revascularisation and statin therapy: A systematic review and meta-analysis of randomized and non-randomized studies - The Cardiac Rehabilitation Outcome Study (CROS). Eur J Prev Cardiol (2016) 0.75
Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet (2003) 19.90
A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med (2002) 12.84
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA (2002) 11.06
A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med (2003) 9.00
Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a randomised study. Lancet (2002) 8.09
Long distance transport for primary angioplasty vs immediate thrombolysis in acute myocardial infarction. Final results of the randomized national multicentre trial--PRAGUE-2. Eur Heart J (2003) 6.71
A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med (1993) 6.52
Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. JAMA (2000) 6.00
Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J (2003) 4.70
A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. N Engl J Med (1993) 4.49
Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med (1997) 4.36
Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med (2002) 4.25
Cost effectiveness of early discharge after uncomplicated acute myocardial infarction. N Engl J Med (2000) 4.19
Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet (1998) 4.03
Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med (1994) 3.96
Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med (2001) 3.85
Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction. N Engl J Med (1999) 3.81
Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet (2001) 3.58
A randomized trial of transfer for primary angioplasty versus on-site thrombolysis in patients with high-risk myocardial infarction: the Air Primary Angioplasty in Myocardial Infarction study. J Am Coll Cardiol (2002) 3.52
Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review. JAMA (1997) 3.51
A randomized comparison of percutaneous transluminal coronary angioplasty by the radial, brachial and femoral approaches: the access study. J Am Coll Cardiol (1997) 3.33
Increased coronary perforation in the new device era. Incidence, classification, management, and outcome. Circulation (1994) 3.30
A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med (1987) 3.04
Thrombolysis with tissue plasminogen activator in acute myocardial infarction: no additional benefit from immediate percutaneous coronary angioplasty. Lancet (1988) 2.90
Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med (2001) 2.83
Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts. Circulation (2002) 2.53
Clinical characteristics and outcome of patients with early (<2 h), intermediate (2-4 h) and late (>4 h) presentation treated by primary coronary angioplasty or thrombolytic therapy for acute myocardial infarction. Eur Heart J (2002) 2.49
The volume of primary angioplasty procedures and survival after acute myocardial infarction. National Registry of Myocardial Infarction 2 Investigators. N Engl J Med (2000) 2.44
Recognition of the importance of embolization in atherosclerotic vascular disease. Circulation (2000) 2.43
Primary stent implantation is superior to balloon angioplasty in acute myocardial infarction: final results of the primary angioplasty versus stent implantation in acute myocardial infarction (PASTA) trial. PASTA Trial Investigators. Catheter Cardiovasc Interv (1999) 2.23
Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial. J Am Coll Cardiol (1999) 2.23
A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: the PACT trial. PACT investigators. Plasminogen-activator Angioplasty Compatibility Trial. J Am Coll Cardiol (1999) 2.14
Reperfusion therapy in elderly patients with acute myocardial infarction: a randomized comparison of primary angioplasty and thrombolytic therapy. J Am Coll Cardiol (2002) 2.13
One-year survival following early revascularization for cardiogenic shock. JAMA (2001) 2.10
Ten-year incidence of myocardial infarction and prognosis after infarction. Department of Veterans Affairs Cooperative Study of Coronary Artery Bypass Surgery. Circulation (1991) 2.09
Cardiogenic shock after acute myocardial infarction. Incidence and mortality from a community-wide perspective, 1975 to 1988. N Engl J Med (1991) 1.99
Incidence and treatment of 'no-reflow' after percutaneous coronary intervention. Circulation (1994) 1.98
Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. Circulation (1999) 1.83
Acute myocardial infarction: pre-hospital and in-hospital management. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J (1996) 1.81
The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. Eur Heart J (2000) 1.72
Primary percutaneous coronary interventions in patients with acute myocardial infarction and prior coronary artery bypass grafting. Am Heart J (2001) 1.72
Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials. Circulation (2001) 1.70
Safety of femoral closure devices after percutaneous coronary interventions in the era of glycoprotein IIb/IIIa platelet blockade. Am J Cardiol (2000) 1.69
Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial. Circulation (2002) 1.68
Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation (1998) 1.63
Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction: results from the SPEED (GUSTO-4 Pilot) Trial. J Am Coll Cardiol (2000) 1.63
Thrombolysis in Myocardial Infarction (TIMI) phase II trial: outcome comparison of a "conservative strategy" in community versus tertiary hospitals. The TIMI Research Group. J Am Coll Cardiol (1990) 1.62
Outcome after combined reperfusion therapy for acute myocardial infarction, combining pre-hospital thrombolysis with immediate percutaneous coronary intervention and stent. Eur Heart J (2001) 1.61
Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER study). The ERASER Investigators. Circulation (1999) 1.58
Treatment of no-reflow in degenerated saphenous vein graft interventions: comparison of intracoronary verapamil and nitroglycerin. Cathet Cardiovasc Diagn (1996) 1.54
Activated clotting times and activated partial thromboplastin times in patients undergoing coronary angioplasty who receive bolus doses of heparin. Cathet Cardiovasc Diagn (1992) 1.52
Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events: data from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) Trial. Circulation (2001) 1.50
Effect of age on the outcome of angioplasty for acute myocardial infarction among patients treated at the Mayo Clinic. Am J Med (2000) 1.48
Features and outcome of no-reflow after percutaneous coronary intervention. Am J Cardiol (1995) 1.43
A randomized controlled trial of hospital discharge three days after myocardial infarction in the era of reperfusion. N Engl J Med (1988) 1.39
Importance of time to reperfusion for 30-day and late survival and recovery of left ventricular function after primary angioplasty for acute myocardial infarction. J Am Coll Cardiol (1998) 1.39
Angiographic outcome after intracoronary X-Sizer helical atherectomy and thrombectomy: first use in humans. Catheter Cardiovasc Interv (2002) 1.39
Use of aortic counterpulsation to improve sustained coronary artery patency during acute myocardial infarction. Results of a randomized trial. The Randomized IABP Study Group. Circulation (1994) 1.39
Cardiogenic shock complicating acute myocardial infarction: the use of coronary angioplasty and the integration of the new support devices into patient management. J Am Coll Cardiol (1992) 1.31
Safety and cost-effectiveness of early discharge after primary angioplasty in low risk patients with acute myocardial infarction. PAMI-II Investigators. Primary Angioplasty in Myocardial Infarction. J Am Coll Cardiol (1998) 1.29
Beneficial effect of intracoronary verapamil on microvascular and myocardial salvage in patients with acute myocardial infarction. J Am Coll Cardiol (1997) 1.28
Intracoronary thrombectomy with the X-sizer catheter system improves epicardial flow and accelerates ST-segment resolution in patients with acute coronary syndrome: a prospective, randomized, controlled study. Circulation (2002) 1.25
Relation of time to treatment and mortality in patients with acute myocardial infarction undergoing primary coronary angioplasty. Am J Cardiol (2002) 1.19
Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart (2001) 1.16
Myocardial salvage after coronary stenting plus abciximab versus fibrinolysis plus abciximab in patients with acute myocardial infarction: a randomised trial. Lancet (2002) 1.14
Importance of time to reperfusion on outcomes with primary coronary angioplasty for acute myocardial infarction (results from the Stent Primary Angioplasty in Myocardial Infarction Trial). Am J Cardiol (2001) 1.13
Predictive factors for development of the no-reflow phenomenon in patients with reperfused anterior wall acute myocardial infarction. J Am Coll Cardiol (2001) 1.08
Influence of prehospital administration of aspirin and heparin on initial patency of the infarct-related artery in patients with acute ST elevation myocardial infarction. J Am Coll Cardiol (2002) 1.08
Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. J Am Coll Cardiol (2000) 1.04
Effect of age on outcome with primary angioplasty versus thrombolysis. J Am Coll Cardiol (1999) 1.04
Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol (2001) 1.03
Use of vascular sealing devices (VasoSeal and Perclose) versus assisted manual compression (Femostop) in transcatheter coronary interventions requiring abciximab (ReoPro). Catheter Cardiovasc Interv (1999) 1.03
A comparison of systematic stenting and conventional balloon angioplasty during primary percutaneous transluminal coronary angioplasty for acute myocardial infarction. STENTIM-2 Investigators. J Am Coll Cardiol (2000) 1.01
A randomized comparison of direct stenting with conventional stent implantation in selected patients with acute myocardial infarction. J Am Coll Cardiol (2002) 0.99
A clinical trial comparing primary stenting of the infarct-related artery with optimal primary angioplasty for acute myocardial infarction: results from the Florence Randomized Elective Stenting in Acute Coronary Occlusions (FRESCO) trial. J Am Coll Cardiol (1998) 0.98
Treatment of no-reflow and impaired flow with the nitric oxide donor nitroprusside following percutaneous coronary interventions: initial human clinical experience. J Am Coll Cardiol (2001) 0.98
Six-month clinical and angiographic follow-up after direct angioplasty for acute myocardial infarction. Final results from the Primary Angioplasty Registry. Circulation (1994) 0.98
Contemporary reperfusion therapy for cardiogenic shock: the GUSTO-I trial experience. The GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol (1995) 0.96
Long term outcome and cost-effectiveness of stenting versus balloon angioplasty for acute myocardial infarction. Heart (2001) 0.96
Low-molecular-weight heparin therapy in percutaneous coronary intervention: the NICE 1 and NICE 4 trials. National Investigators Collaborating on Enoxaparin Investigators. J Invasive Cardiol (2000) 0.96
Predictors of cardiogenic shock after thrombolytic therapy for acute myocardial infarction. J Am Coll Cardiol (2000) 0.94
Effects of Abciximab on the architecture of platelet-rich clots in patients with acute myocardial infarction undergoing primary coronary intervention. Circulation (2001) 0.93
Transradial approach for coronary angioplasty in the setting of acute myocardial infarction: a dual-center registry. Catheter Cardiovasc Interv (2002) 0.93
Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Strategies for Patency Enhancement in the Emergency Department (SPEED) Group. Circulation (2000) 0.92
In-hospital and late results of coronary stents versus conventional balloon angioplasty in acute myocardial infarction (GRAMI trial). Gianturco-Roubin in Acute Myocardial Infarction. Am J Cardiol (1998) 0.91
A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention. J Am Coll Cardiol (2002) 0.91
Clinical and angiographic follow-Up after primary stenting in acute myocardial infarction: the Primary Angioplasty in Myocardial Infarction (PAMI) stent pilot trial. Circulation (1999) 0.90
Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med (2001) 9.31
A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med (1996) 6.05
A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. N Engl J Med (1993) 4.49
Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet (1999) 4.36
Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction. N Engl J Med (1999) 3.81
Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. Zwolle Myocardial Infarction Study Group. Circulation (1998) 3.70
Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review. JAMA (1997) 3.51
Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I Investigators. Circulation (1995) 3.38
Plasma malondialdehyde as biomarker for oxidative stress: reference interval and effects of life-style factors. Clin Chem (1997) 3.02
Transferring patients for primary angioplasty: a retrospective analysis of 104 selected high risk patients with acute myocardial infarction. Heart (1997) 2.93
Thrombolysis with tissue plasminogen activator in acute myocardial infarction: no additional benefit from immediate percutaneous coronary angioplasty. Lancet (1988) 2.90
Diagnostic efficiency of troponin T measurements in acute myocardial infarction. Circulation (1991) 2.87
Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med (2001) 2.83
Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med (2008) 2.61
Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators. Circulation (1995) 2.53
Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO) trial. Circulation (2001) 2.34
Increased neutrophil-platelet adhesion in patients with unstable angina. Circulation (1996) 2.20
Percutaneous transluminal coronary angioplasty versus thrombolysis in acute myocardial infarction. Scand Cardiovasc J (2000) 2.03
Stenting of the arterial duct: a new approach to palliation for pulmonary atresia. Br Heart J (1992) 1.98
Activated platelets induce monocyte chemotactic protein-1 secretion and surface expression of intercellular adhesion molecule-1 on endothelial cells. Circulation (1998) 1.95
Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients. J Thromb Haemost (2007) 1.91
Platelet function in septic multiple organ dysfunction syndrome. Intensive Care Med (1997) 1.91
Randomized comparison of coronary stenting with balloon angioplasty in selected patients with acute myocardial infarction. Circulation (1998) 1.87
Effect of highly bioaccumulated polychlorinated biphenyl congeners on estrogen and androgen receptor activity. Toxicology (2001) 1.84
Predictive factors of restenosis after coronary stent placement. J Am Coll Cardiol (1997) 1.84
Determinants of prognosis in survivors of myocardial infarction: a prospective clinical angiographic study. N Engl J Med (1982) 1.79
Influence of treatment delay on infarct size and clinical outcome in patients with acute myocardial infarction treated with primary angioplasty. J Am Coll Cardiol (1998) 1.77
Clinical value of 12-lead electrocardiogram after successful reperfusion therapy for acute myocardial infarction. Zwolle Myocardial infarction Study Group. Lancet (1997) 1.77
Platelet function in acute myocardial infarction treated with direct angioplasty. Circulation (1996) 1.75
Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. J Am Coll Cardiol (1998) 1.73
The impact of an end-point committee in a large multicentre, randomized, placebo-controlled clinical trial: results with and without the end-point committee's final decision on end-points. Eur Heart J (1999) 1.72
Long-term recovery of left ventricular function after primary angioplasty for acute myocardial infarction. Eur Heart J (2001) 1.71
Influence of stent design on 1-year outcome after coronary stent placement: a randomized comparison of five stent types in 1,147 unselected patients. Catheter Cardiovasc Interv (2000) 1.65
Randomized, double-blind study comparing saruplase with streptokinase therapy in acute myocardial infarction: the COMPASS Equivalence Trial. Comparison Trial of Saruplase and Streptokinase (COMASS) Investigators. J Am Coll Cardiol (1998) 1.64
Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction: results from the SPEED (GUSTO-4 Pilot) Trial. J Am Coll Cardiol (2000) 1.63
Vessel size and long-term outcome after coronary stent placement. Circulation (1998) 1.61
Gene expression profiling of human stent-induced neointima by cDNA array analysis of microscopic specimens retrieved by helix cutter atherectomy: Detection of FK506-binding protein 12 upregulation. Circulation (2001) 1.61
A randomized comparison of intra-aortic balloon pumping after primary coronary angioplasty in high risk patients with acute myocardial infarction. Eur Heart J (1999) 1.61
Irregular coronary lesion morphology after thrombolysis predicts early clinical instability. J Am Coll Cardiol (1991) 1.58
Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents: a comparison of TNK-tPA and rt-PA. Eur Heart J (2001) 1.58
Randomized comparison of primary coronary angioplasty with thrombolytic therapy in low risk patients with acute myocardial infarction. J Am Coll Cardiol (1997) 1.57
Coronary lesion morphology in acute myocardial infarction: demonstration of early remodeling after streptokinase treatment. J Am Coll Cardiol (1990) 1.56
Increased risk of restenosis after placement of gold-coated stents: results of a randomized trial comparing gold-coated with uncoated steel stents in patients with coronary artery disease. Circulation (2000) 1.56
Operator volume and outcome of patients undergoing coronary stent placement. J Am Coll Cardiol (1998) 1.56
Mortality, reinfarction, left ventricular ejection fraction and costs following reperfusion therapies for acute myocardial infarction. Eur Heart J (1996) 1.54
Influence of vitamin D receptor gene polymorphisms on mortality risk in hemodialysis patients. Am J Kidney Dis (2001) 1.52
Acute coronary syndromes in the GUSTO-IIb trial: prognostic insights and impact of recurrent ischemia. The GUSTO-IIb Investigators. Circulation (1998) 1.52
Coronary artery revascularization in patients with sustained ventricular arrhythmias in the chronic phase of a myocardial infarction: effects on the electrophysiologic substrate and outcome. J Am Coll Cardiol (2001) 1.51
Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised double blind European Cooperative Study Group trial. Br Heart J (1992) 1.50
Comparison of angiography and intravascular ultrasound for the assessment of lumen size after coronary stent placement: impact of dilation pressures. Cathet Cardiovasc Diagn (1997) 1.49
Feasibility of early discharge after acute Q wave myocardial infarction in patients not receiving thrombolytic treatment. J Am Coll Cardiol (1993) 1.48
Role of collateral circulation in the acute phase of ST-segment-elevation myocardial infarction treated with primary coronary intervention. Eur Heart J (2004) 1.48
Limitation of myocardial infarct size after primary angioplasty: is a higher patency the only mechanism? Am Heart J (1999) 1.43
Carvedilol for prevention of restenosis after directional coronary atherectomy : final results of the European carvedilol atherectomy restenosis (EUROCARE) trial. Circulation (2000) 1.43
An analysis of the arterial input curve for technetium-99m-HMPAO: quantification of rCBF using single-photon emission computed tomography. J Nucl Med (1991) 1.42
Composition of coronary plaques obtained by directional atherectomy in stable angina: its relation to serum lipids and statin treatment. J Intern Med (2006) 1.41
Myocardial infarction with normal coronary arteries: a prospective clinical-angiographic study. Am J Cardiol (1981) 1.39
The effect of a low molecular mass thrombin inhibitor, inogatran, and heparin on thrombin generation and fibrin turnover in patients with unstable coronary artery disease. Eur Heart J (1999) 1.39
[Improvement in the treatment of acute myocardial infarct by the establishment of a thrombolysis unit in a cardiology servic]. Rev Esp Cardiol (1998) 1.39
Coronary risk factors and silent ischemic heart disease. The ECCIS Project. Int J Cardiol (1994) 1.39
Myocardial scintigraphy with iodine-123 phenylpentadecanoic acid and thallium-201 in patients with coronary artery disease: a comparative dual-isotope study. Eur J Nucl Med (1992) 1.38
Early recovery of coronary flow reserve after stent implantation as assessed by positron emission tomography. J Am Coll Cardiol (1999) 1.38
[Intravenous diclofenac sodium in the treatment of nephritic colic]. Rev Clin Esp (1989) 1.38
Four-year experience with Palmaz-Schatz stenting in coronary angioplasty complicated by dissection with threatened or present vessel closure. Circulation (1994) 1.31
Endocrine-disrupting chemicals and obesity development in humans: a review. Obes Rev (2011) 1.30
Glycosylated haemoglobin in renal failure. Diabetologia (1980) 1.30
The influence of heart rate on the Doppler-derived myocardial performance index. J Am Soc Echocardiogr (2000) 1.28
Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet (1996) 1.26
Influence of infarct-zone viability on left ventricular remodeling after acute myocardial infarction. Circulation (1997) 1.25
Influence of lesion length on restenosis after coronary stent placement. Am J Cardiol (1999) 1.25
Restenosis after coronary placement of various stent types. Am J Cardiol (2001) 1.24
Telemedicine used for remote prehospital diagnosing in patients suspected of acute myocardial infarction. J Intern Med (2002) 1.23
Regional myocardial blood flow in patients with sick sinus syndrome randomized to long-term single chamber atrial or dual chamber pacing--effect of pacing mode and rate. J Am Coll Cardiol (2000) 1.18
Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial. Circulation (1996) 1.16
Myocardial damage, inflammation and thrombin inhibition in unstable coronary artery disease. Eur Heart J (2003) 1.16
Differences in prognostic factors and outcomes between women and men undergoing coronary artery stenting. JAMA (2000) 1.16
Hepatic hemodynamics and the renin-angiotensin-aldosterone system in cirrhosis. Gastroenterology (1980) 1.14
Assessment of left ventricular performance during percutaneous transluminal coronary angioplasty: a study by intravenous digital subtraction ventriculography. Br Heart J (1988) 1.11
Prolapse of the posterior leaflet of the mitral valve associated with secundum atrial septal defect. Am J Cardiol (1975) 1.08
Angiographic findings 1 month after myocardial infarction: a prospective study of 259 survivors. Circulation (1982) 1.08
Circumflex artery-related acute myocardial infarction: limited ECG abnormalities but poor outcome. Neth Heart J (2007) 1.07
Five year outcome after primary coronary intervention for acute ST elevation myocardial infarction: results from a single centre experience. Heart (2005) 1.06
Vitronectin receptor (alpha(v)beta3) mediates platelet adhesion to the luminal aspect of endothelial cells: implications for reperfusion in acute myocardial infarction. Circulation (1997) 1.06
Heart failure and echocardiographic changes during long-term follow-up of patients with sick sinus syndrome randomized to single-chamber atrial or ventricular pacing. Circulation (1998) 1.06
Protective role against restenosis from an interleukin-1 receptor antagonist gene polymorphism in patients treated with coronary stenting. J Am Coll Cardiol (2000) 1.06
Regulation of monocyte procoagulant activity in acute myocardial infarction: role of tissue factor and tissue factor pathway inhibitor-1. Blood (2001) 1.05
Increased amounts of collagenase and gelatinase in porcine myocardium following ischemia and reperfusion. J Mol Cell Cardiol (1998) 1.04
Primary PCI as the preferred reperfusion therapy in STEMI: it is a matter of time. Heart (2009) 1.04
Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol (2001) 1.03
Induction of cytokine expression in leukocytes in acute myocardial infarction. J Am Coll Cardiol (1997) 1.03
Relation between ST-segment changes and myocardial perfusion evaluated by myocardial contrast echocardiography in patients with acute myocardial infarction treated with direct angioplasty. Am J Cardiol (1998) 1.03
Dysregulation of monocytic nuclear factor-kappa B by oxidized low-density lipoprotein. Arterioscler Thromb Vasc Biol (1997) 1.01
Time course of restenosis during the first year after emergency coronary stenting. Circulation (1993) 1.01
Restrictive cardiomyopathy in pseudoxanthoma elasticum. Chest (1980) 1.01